Concord Biotech profit and loss

Latest FY26

Revenue: ₹1,055cr−12.1% on FY25
EBITDA: ₹367cr−27.4% on FY25
Net profit: ₹259cr−30.2% on FY25
EPS: ₹24.78−30.2% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024

Expenses
	1,170	1,055	1,200	1,017
	48.3	52.4	44.4	33.8
	1,219	1,107	1,245	1,051
	271	254	264	185
	63.6	62.6	56.0	56.7
	−54.9	−71.3	−14.8	−12.1
	191	177	139	123
	0.2	0.3	0.5	2.6
	74.8	74.5	54.4	53.6
	296	265	249	233
	841	762	749	642
	404	367	506	432
	330	293	452	378
Profit
	378	345	496	409
	−3.3	−3.3	0.0	0.0
	374	342	496	409
	95.6	86.3	119	99.8
	−0.9	−0.9	3.9	4.6
	94.7	85.4	123	104
	−0.3	2.9	−1.3	3.4
	279	259	372	308
	280	256	373	305
	44.7	55.2	6.0	−0.0
	324	314	378	308
	282	261	372	308
	−3.1	−1.7	0.0	—
Per share
	₹26.71	₹24.78	₹35.52	₹29.45
	₹26.71	₹24.78	₹35.52	₹29.45
Other comprehensive income — detail
	44.7	55.2	6.0	—
	45.3	55.8	6.0	−0.0
	0.4	0.5	0.0	—
	−0.3	0.0	—	—
	327	316	378	308
	−3.2	−1.8	0.0	0.0
Per share — as-filed variants
	₹26.71	₹24.78	₹35.52	₹29.45
	₹26.71	₹24.78	₹35.52	₹29.45
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	891	809	895	788
	76.1%	76.7%	74.5%	77.5%
Adjusted (ex-exceptional items) — derived
	378	345	496	409
	−3.3	−3.3	0.0	0.0
	282	262	372	308
	₹26.94	₹25.01	₹35.52	₹29.45

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

CONCORDBIO₹1,230.60

Concord Biotech Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersBIOCON DIVISLAB CAPLIPOINT EMCURE BLUEJET ERIS GRANULES ACUTAASMcap ₹12,874 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	—	1,016.9	1,200.1	1,054.9	1,170.4
Other Income	—	33.8	44.4	52.4	48.3
Total Income	—	1,050.7	1,244.5	1,107.2	1,218.7
Expenses
+ Cost of Materials Consumed	—	184.5	264.3	254.3	270.7
+ Purchases of Stock-in-Trade	—	56.7	56.0	62.6	63.6
+ Changes in Inventories	—	-12.1	-14.8	-71.3	-54.9
+ Employee Benefit Expense	—	123.0	138.9	176.9	190.5
+ Finance Costs	—	2.6	0.5	0.3	0.2
+ Depreciation & Amortisation	—	53.6	54.4	74.5	74.8
+ Other Expenses	—	233.1	249.3	264.9	296.2
Total Expenses	—	641.5	748.7	762.2	841.1
EBITDA	—	431.6	506.3	367.4	404.3
EBIT	—	378.0	452.0	292.9	329.5
Profit
PBT before Exceptional Items	—	409.2	495.9	345.0	377.6
+ Exceptional Items	—	0.0	0.0	-3.3	-3.3
Pretax Income	—	409.2	495.9	341.7	374.3
+ Current Tax	—	99.8	119.0	86.3	95.6
+ Deferred Tax	—	4.6	3.9	-0.9	-0.9
Tax Expense	—	104.5	122.9	85.4	94.7
+ Share of Associates & JVs	—	3.4	-1.3	2.9	-0.3
Net Income	—	308.1	371.6	259.2	279.4
+ Net Income — Continuing Ops	—	304.7	373.0	256.3	279.6
+ Other Comprehensive Income	—	-0.0	6.0	55.2	44.7
Total Comprehensive Income	—	308.1	377.6	314.5	324.0
Net Income to Common	—	308.1	371.6	260.9	282.4
Minority Interest	—	—	0.0	-1.7	-3.1
Per Share
Basic EPS	—	29.45	35.52	24.78	26.71
Diluted EPS	—	29.45	35.52	24.78	26.71
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	6.0	55.2	44.7
+ Items NOT to be Reclassified to P&L	—	-0.0	6.0	55.8	45.3
+ Tax on Items NOT to be Reclassified	—	—	0.0	0.5	0.4
+ Items to be Reclassified to P&L	—	—	—	0.0	-0.3
Comprehensive Income — Owners of Parent	—	308.1	377.6	316.3	327.3
Comprehensive Income — Non-controlling Interests	—	0.0	0.0	-1.8	-3.2
Per Share — as-filed variants
Basic EPS — Continuing Operations	—	29.45	35.52	24.78	26.71
Diluted EPS — Continuing Operations	—	29.45	35.52	24.78	26.71
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	—	787.7	894.6	809.2	891.0
Gross Margin %	—	77.46	74.54	76.71	76.13
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	—	409.2	495.9	345.0	377.6
− Exceptional Items (reconciliation)	—	0.0	0.0	-3.3	-3.3
Net Income Adj (tax-effected)	—	308.1	371.6	261.7	281.8
EPS Adj	—	29.45	35.52	25.01	26.94
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	—	1.00	1.00	1.00	1.00
Paid Up Equity Capital	—	10.5	10.5	10.5	10.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.